Recombinant Anti-PTEN antibody [Y184] (ab32199)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [Y184] to PTEN
- Suitable for: WB
- Knockout validated
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-PTEN antibody [Y184]
See all PTEN primary antibodies -
Description
Rabbit monoclonal [Y184] to PTEN -
Host species
Rabbit -
Specificity
A 42kDa band is seen for some samples in addition to 50-54kDa band- we do not know the specificity of this band. For example Rat kidney, heart, spleen have bands around 50kDa but rat PC-12 cells have single band at ~42kDa. -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat -
Immunogen
Synthetic peptide within Human PTEN aa 350 to the C-terminus (C terminal). The exact sequence is proprietary.
(Peptide available asab157804) -
Positive control
- WB: HAP1, MCF7 and HEK-293 cell lysates; Human brain lysate; Mouse primary bone marrow derived macrophage whole cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
Y184 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab32199 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (10) |
1/10000. Detects a band of approximately 54 kDa (predicted molecular weight: 47 kDa).
For unpurified, use 1/500. |
Notes |
---|
WB
1/10000. Detects a band of approximately 54 kDa (predicted molecular weight: 47 kDa). For unpurified, use 1/500. |
Target
-
Function
Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement.
Isoform alpha: Functional kinase, like isoform 1 it antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in mitochondrial energetic metabolism by promoting COX activity and ATP production, via collaboration with isoform 1 in increasing protein levels of PINK1. -
Tissue specificity
Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas. -
Involvement in disease
Cowden syndrome 1
Lhermitte-Duclos disease
Bannayan-Riley-Ruvalcaba syndrome
Squamous cell carcinoma of the head and neck
Endometrial cancer
PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.
Glioma 2
VACTERL association with hydrocephalus
Prostate cancer
Macrocephaly/autism syndrome
A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome. -
Sequence similarities
Contains 1 C2 tensin-type domain.
Contains 1 phosphatase tensin-type domain. -
Domain
The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function. -
Post-translational
modificationsConstitutively phosphorylated by CK2 under normal conditions. Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding. Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from ubiquitin-mediated degradation probably by inhibiting its binding to NEDD4. Phosphorylation by ROCK1 is essential for its stability and activity. Phosphorylation by PLK3 promotes its stability and prevents its degradation by the proteasome.
Monoubiquitinated; monoubiquitination is increased in presence of retinoic acid. Deubiquitinated by USP7; leading to its nuclear exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated by XIAP/BIRC4. -
Cellular localization
Secreted. May be secreted via a classical signal peptide and reenter into cells with the help of a poly-Arg motif and Cytoplasm. Nucleus. Nucleus, PML body. Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies. XIAP/BIRC4 promotes its nuclear localization. - Information by UniProt
-
Database links
- Entrez Gene: 5728 Human
- Entrez Gene: 19211 Mouse
- Entrez Gene: 50557 Rat
- Omim: 601728 Human
- SwissProt: P60484 Human
- SwissProt: O08586 Mouse
- Unigene: 500466 Human
- Unigene: 729457 Human
see all -
Alternative names
- 10q23del antibody
- BZS antibody
- DEC antibody
see all
Images
-
Lanes 1 and 5: PTEN knockout HAP1 cell lysate (20 µg)
Lanes 2 and 6: Wild-type HAP1 cell lysate (20 µg)
Lane 2: Green signal from target – ab32199 observed at 47 kDa
Lanes 3 and 4: Red signal from loading control – ab8245 observed at 37 kDa
Lanes 5 and 6: Merged (red and green) signalab32199 was shown to specifically recognize PTEN in wild-type HAP1 cells along with additional cross reactive bands. No band was observed when PTEN knockout samples were used. Wild-type and PTEN knockout samples were subjected to SDS-PAGE, ab32199 and ab8245 (loading control to GAPDH) were diluted to 1/500 and 1/2000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 h at room temperature before imaging.
-
Lanes 1: PTEN knockout HAP1 cell lysate (20 µg)
Lanes 2: Wild-type HAP1 cell lysate (20 µg)
Green signal from target
Red signal from loading control – ab8245 observed at 37 kDaThis western blot image is a comparison between ab32199 and a competitor's top cited mouse monoclonal antibody.
-
All lanes : Anti-PTEN antibody [Y184] (ab32199) at 1/10000 dilution (purified)
All lanes : Brain lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Anti-rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 47 kDa
Observed band size: 54 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST -
All lanes : Anti-PTEN antibody [Y184] (ab32199) at 1/10000 dilution (purified)
Lane 1 : MCF7 whole cell lysate
Lane 2 : HEK293 whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Anti-rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 47 kDa
Observed band size: 54 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST -
Anti-PTEN antibody [Y184] (ab32199) at 1/500 dilution (Unpurified) + MCF7 cell lysate
Predicted band size: 47 kDa
Observed band size: 54 kDa why is the actual band size different from the predicted? -
All lanes : Anti-PTEN antibody [Y184] (ab32199) at 1/500 dilution (Unpurified)
All lanes : Mouse primary bone marrow derived macrophage whole cell lysate
Lysates/proteins at 50 µg per lane.
Secondary
All lanes : HRP-conjugated goat anti-rabbit IgG polyclonal
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 47 kDa
Observed band size: 50 kDa why is the actual band size different from the predicted?
Exposure time: 30 secondsTreatment:
Lane 1 - control siRNA 24 hours
Lane 2 - PTEN siRNA 24 hours
Lane 3 - control siRNA 48 hours
Lane 4 - PTEN siRNA 48 hours
-
Anti-PTEN antibody [Y184] (ab32199) at 1/500 dilution + RBL-2H3 whole cell lysate
Secondary
Goat Anti-rabbit HRP at 1/1000 dilution
Developed using the ECL technique.
Predicted band size: 47 kDa
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (247)
ab32199 has been referenced in 247 publications.
- Obayashi F et al. Identification of a Cowden syndrome patient with a novel PTEN mutation and establishment of patient-derived induced pluripotent stem cells. In Vitro Cell Dev Biol Anim 58:69-78 (2022). PubMed: 34984555
- Chowdhury SG et al. DNA damage induced cellular senescence and it's PTEN-armed exosomes-the warriors against prostate carcinoma cells. Med Oncol 39:34 (2022). PubMed: 35059876
- Hsiao YW et al. Disruption of the pentraxin 3/CD44 interaction as an efficient therapy for triple-negative breast cancers. Clin Transl Med 12:e724 (2022). PubMed: 35090088
- Jang SH et al. The phosphatase and tensin homolog gene inserted between NP and P gene of recombinant New castle disease virus oncolytic effect test to glioblastoma cell and xenograft mouse model. Virol J 19:21 (2022). PubMed: 35093115
- Li W et al. miRNA-21 plays an important role in necrotizing enterocolitis. Arch Med Sci 18:406-412 (2022). PubMed: 35316914